BioFocus Extends its Collaboration with The Michael J. Fox Foundation
News Apr 18, 2013
BioFocus has announced that it has extended its collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.
Based on the success of the project to date, BioFocus will continue the optimization of agents for disease specific biomarkers.
“We have worked with The Michael J. Fox Foundation since 2011 to identify and optimize a-synuclein imaging agents, and are delighted that the progress supports an extension to this collaboration,” said Dr Chris Newton, Managing Director, BioFocus.
Dr Newton continued, “The program will utilize BioFocus' leading biology and chemistry platforms, and will capitalize on the company’s highly experienced teams and state-of-the-art technologies.”
Protein's Role in Mitochondrial Metabolism IdentifiedNews
EXD2, a protein previously thought to be localised to the nucleus, has a key role in the production of proteins by mitochondria.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE
Tweak to Technique Could Bolster Disease DetectionNews
A team of Stanford researchers has developed a technique that they hope could more precisely detect diseases or disorders such as cancer or a heart attack.READ MORE